A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Latest Information Update: 15 Oct 2024
At a glance
- Drugs BGB-16673 (Primary) ; Sonrotoclax; Zanubrutinib
- Indications B-cell lymphoma
- Focus Adverse reactions
- Sponsors BeiGene
- 15 Oct 2024 New trial record